---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-001073"
form_type: "8-K"
ticker: "ALMS"
cik: "0001847367"
company_name: "ALUMIS INC."
filed_at: "2026-01-06T23:59:59+00:00"
generated_at: "2026-05-16T11:33:34.577340+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Alumis Phase 3 oral psoriasis drug envudeucitinib meets all endpoints; NDA planned H2 2026

## Summary
- Both ONWARD1 and ONWARD2 trials met co-primary endpoints PASI 75 and sPGA 0/1 at Week 16 (p<0.0001).
- At Week 24, ~65% achieved PASI 90 and >40% PASI 100, on average across trials.
- Safety profile consistent with Phase 2; most common TEAEs were headaches, nasopharyngitis, URIs, and acne.
- Envudeucitinib also superior vs apremilast on PASI endpoints at Week 24 (p<0.0001).
- Alumis to submit NDA to FDA in H2 2026; topline from SLE Phase 2b expected Q3 2026.

## SEC filing metadata
- accession: 0001104659-26-001073
- form_type: 8-K
- ticker: ALMS
- cik: 0001847367
- company_name: ALUMIS INC.
- filed_at: 2026-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/0001104659-26-001073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-001073
- JSON: https://secwatch.observer/filing/0001104659-26-001073.json
- Plain text: https://secwatch.observer/filing/0001104659-26-001073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.